-
s Immune Checkpoint Inhibitor-Mediated Cardiovascular Disease: The Dark Side of the Monoclonal Anti-Body Therapy against Cancer
- Source: Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Volume 23, Issue 11, Sep 2023, p. 1365 - 1367
-
- 01 Sep 2023
Preview this article:




Immune Checkpoint Inhibitor-Mediated Cardiovascular Disease: The Dark Side of the Monoclonal Anti-Body Therapy against Cancer, Page 1 of 1
< Previous page Next page > /docserver/preview/fulltext/emiddt/23/11/s4-1.gif
There is no abstract available.
© Bentham Science Publishers